Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Nuscale Power Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $868.62M), while Nuscale Power Corporation trades at $9.74 (market cap $4.06B). The key difference: Nuscale Power Corporation is far larger — about 4.7× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| AMPH | SMR | |
|---|---|---|
Market Cap | $868.62M | $4.06B |
Sector | Health | Utilities |
52-Week High | $30.81 | $53.43 |
52-Week Low | $16.87 | $7.59 |
Enterprise Value | $1.27B | $2.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
NuScale Power (SMR) trades at $9.83, up 3.69% with a bullish technical signal. The company reported Q2 2026 earnings that met estimates but revenues plunged 98.8% as RoPower work wound down. Despite negative profit margins and cash burn, NuScale maintains $1.9 billion liquidity and is advancing commercialization of its NRC-approved small modular reactor technology amid growing AI power demand.
The outlook hinges on successful commercial deployment of SMR technology, with potential for significant upside if large-scale projects materialize. Key risks include execution challenges, revenue volatility, and intense competition in the nuclear energy sector. Analyst consensus suggests 8% upside to the $10.63 price target, but investors should weigh the high-risk, high-reward nature of this pre-revenue growth story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
